Rotigotine transdermal patch in the treatment of Parkinson’s disease and restless legs syndrome

Bibliography

• JANKOVIC J: Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. (2005)20(Suppl. 11):S11-S16.
   PubMed Web of Science ®Google Scholar
• NUTT JG: Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa? Mov. Disord. (2007) 22(1):1-9.
   PubMed Web of Science ®Google Scholar
• DIAMOND A, JANKOVIC J: Treatment of advanced Parkinson's disease. Expert Rev. Neurother. (2006) 6(8):1181-1197.
   PubMedGoogle Scholar
• A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin. Neuropharmacol. (2000) 23(1):34-44.
   PubMed Web of Science ®Google Scholar
• RASCOL O, BROOKS DJ, KORCZYN AD et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. (2000) 342(20):1484-1491.
   PubMed Web of Science ®Google Scholar
• TINTNER R, JANKOVIC J: Dopamine agonists in Parkinson's disease. Expert Opin. Investig. Drugs (2003) 12(11):1803-1820.
   PubMed Web of Science ®Google Scholar
• JENNER P: A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology (2005) 65(2 Suppl.1):S3-S5.
   PubMedGoogle Scholar
• RUPNIAK NM, TYE SJ, JENNINGS CA et al.: Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Neurology (1989) 39(3):329-335.
   PubMed Web of Science ®Google Scholar
• REYNOLDS NA, WELLINGTON K, EASTHOPE SE: Rotigotine: in Parkinson's disease. CNS Drugs (2005) 19(11):973-981.
   PubMed Web of Science ®Google Scholar
• NAIDU Y, CHAUDHURI KR: Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease. Expert Opin. Drug Deliv. (2007) 4(2):111-118.
   PubMed Web of Science ®Google Scholar
• HUTTON JT, METMAN LV, CHASE TN et al.: Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord. (2001) 16(3):459-463.
   PubMed Web of Science ®Google Scholar
• WATTS RL, JANKOVIC J, WATERS C et al.: Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology (2007) 68:272-276.
   PubMed Web of Science ®Google Scholar
• THE PARKINSON STUDYGROUP: A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol. (2003) 60(12):1721-1728.
   PubMed Web of Science ®Google Scholar
• QUINN N: Rotigotine Transdermal Delivery System (TDS) (SP-962): a multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and efficacy of rotigotine TDS in patients with advanced Parkinson' disease. Parkinsonism Relat. Disord. (2002) 7(Suppl. 1):S66.
   Google Scholar
• LEWITT PA, LYONS KE, PAHWA R: Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology (2007) 68(16):1262-1267.
   PubMed Web of Science ®Google Scholar
• STIASNY-KOLSTER K, KOHNEN R, SCHOLLMAYER E, MOLLER JC, OERTEL WH: Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov. Disord. (2004) 19(12):1432-1438.
   PubMed Web of Science ®Google Scholar
• METMAN LV, GILLESPIE M, FARMER C et al.: Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin. Neuropharmacol. (2001) 24(3):163-169.
   PubMed Web of Science ®Google Scholar
• CALABRESE VP, LLOYD KA, BRANCAZIO P et al.: N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism. Mov. Disord. (1998) 13(5):768-774.
   PubMed Web of Science ®Google Scholar
• POEWE W, LUESSI F: Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology (2005) 65(2 Suppl.1):S11-S14.
   PubMed Web of Science ®Google Scholar
• BELLUZZI JD, DOMINO EF, MAY JM, BANKIEWICZ KS, MCAFEE DA: N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov. Disord. (1994) 9(2):147-154.
   PubMed Web of Science ®Google Scholar
• VAN DER WEIDE J, DE VRIES JB, TEPPER PG, HORN AS: Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. Eur. J. Pharmacol. (1986) 125(2):273-282.
   PubMed Web of Science ®Google Scholar
• MORGAN JC, SETHI KD: Rotigotine for the treatment of Parkinson's disease. Expert Rev. Neurother. (2006) 6(9):1275-1282.
   PubMed Web of Science ®Google Scholar
• BERTAINA-ANGLADE V, LA ROCHELLE CD, BOYER PA, MOCAER E: Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav. Pharmacol. (2006) 17(8):703-713.
   PubMed Web of Science ®Google Scholar
• SCHELLER D, CHAN P, LI Q et al.: Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp. Neurol. (2007) 203(2):415-422.
   PubMed Web of Science ®Google Scholar
• SPLINTER MY: Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome (February). Ann. Pharmacother. (2007) 41(2):285-295.
   PubMed Web of Science ®Google Scholar
• CAWELLO W, BRAUN M, HORSTMANN R: Pharmacokinetics of transdermal rotigotine in subjects with impaired renal function. J. Clin. Pharmacol. (2005) 45:1091.
   Web of Science ®Google Scholar
• GULDENPFENNIG WM, POOLE KH, SOMMERVILLE KW, BOROOJERDI B: Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin. Neuropharmacol. (2005) 28(3):106-110.
   PubMed Web of Science ®Google Scholar
• BRAUN M, CAWELLO W, POOLE K, HORTSMANN R: Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. 9th Congress of the European Federation of Neurological Societies. Athens, Greece (17 – 20 September 2005) P1245.
   Google Scholar
• JANKOVIC J, WATTS R, MARTIN W, BOROOJERDI B: Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson's disease. Arch. Neurol. (2007) 64(5):676-682.
   PubMed Web of Science ®Google Scholar
• SWART PJ, OELEN WE, BRUINS AP, TEPPER PG, DE ZEEUW RA: Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry. J. Anal. Toxicol. (1994) 18(2):71-77.
   PubMed Web of Science ®Google Scholar
• HANSEN K, BRAUN M, HORSTMANN R: Low drug-drug interaction potential of rotigotine. J. Clin. Pharmacol. (2005) 45:1091.
   Web of Science ®Google Scholar
• GERDING TK, DRENTH BF, DE ZEEUW RA, TEPPER PG, HORN AS: Metabolism and disposition of the dopamine agonist 2-(N-propyl-N-2-thienylethylamino)-5- hydroxytetralin in conscious monkeys after subsequent i.v. oral, and ocular administration. Drug Metab. Dispos. (1990) 18(6):923-928.
   PubMed Web of Science ®Google Scholar
• BIANCHINE J, POOLE K, WOLTERING F: Efficacy and dose response of the novel transdermally applied dopamine agonist rotigotine CDS in early Parkinson's disease. Neurology (2002) 58(Suppl. 3):A162-A163.
   Web of Science ®Google Scholar
• PARKINSON STUDY GROUP: Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA (2000) 284(15):1931-1938.
   PubMed Web of Science ®Google Scholar
• GILADI N, TOLOSA E, BOOTHMAN B: Rotigotine transdermal system in patients with idiopathic Parkinson's disease: results of two placebo- and comparator-controlled trials. World Parkinson Congress. Washington, D.C. (22 – 26 February 2006).
   Google Scholar
• POEWE W, RASCOL O, QUINN N, GILADI N, BOOTHMAN B: Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. (2007) (In press).
   Google Scholar
• PATTON J, NEILSON S, BOROOJERDI B: Tolerability of switching from an oral dopamine agonist to transdermal rotigotine in Parkinson's disease. First World Parkinson's Congress. Washington, D.C., USA (2006)
   Google Scholar
• KORCZYN AD, REICHMANN H, BOROOJERDI B, HACK HJ: Rotigotine transdermal system for perioperative administration. J. Neural Transm. (2007) 114(2):219-221.
   PubMed Web of Science ®Google Scholar
• STIASNY-KOLSTER K, GARCIA-BORREGUERO D, SALETU B et al.: Rotigotine in the treatment of moderate to severe idiopathic restless legs syndrome-a double-blind placebo-controlled multi-center dose-finding study. 56th Annual Meeting of the American Academy of Neurology. San Francisco, USA (2005)
   Google Scholar
• FRUCHT S, ROGERS JD, GREENE PE, GORDON MF, FAHN S: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology (1999) 52(9):1908-1910.
   PubMed Web of Science ®Google Scholar
• WEINTRAUB D, SIDEROWF AD, POTENZA MN et al.: Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch. Neurol. (2006) 63(7):969-973.
   PubMed Web of Science ®Google Scholar
• BABIC T, BOOTHMANN B, POLIVKA J et al.: Rotigotine transdermal patch enables rapid titration to effective doses in advanced-stage idiopathic Parkinson disease: subanalysis of a parallel group, open-label, dose-escalation study. Clin. Neuropharmacol. (2006) 29(4):238-242.
   PubMed Web of Science ®Google Scholar
• CAWELLO W, ELSHOFF P, BOEKENS J, BRAUN M, HORSTMANN R: Characteristics of rotigotine elimination after patch removal. EFNS Poster Presentation, Glasgow, Scotland. Eur. J. Neurol. (2006) 13(S2):42-294.
   PubMedGoogle Scholar